Page last updated: 2024-12-11

5-geranyloxy-7-methoxycoumarin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-geranyloxy-7-methoxycoumarin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6441377
CHEMBL ID4176013
CHEBI ID174428
SCHEMBL ID1714211
SCHEMBL ID1714204
MeSH IDM0409031

Synonyms (32)

Synonym
5-geranyloxy-7-methoxycoumarin
CHEBI:174428
5-[(2e)-3,7-dimethylocta-2,6-dienoxy]-7-methoxychromen-2-one
7380-39-4
5-geranoxy-7-methoxycoumarin
unii-39a7k6nn3w
5-(geranyloxy)-7-methoxycoumarin
2h-1-benzopyran-2-one, 5-((3,7-dimethyl-2,6-octadienyl)oxy)-7-methoxy-, (e)-
herniarin, 5-(geranyloxy)-
5-((3,7-dimethyl-2,6-octadienyl)oxy)-7-methoxycoumarin
coumarin, 5-((3,7-dimethyl-2,6-octadienyl)oxy)-7-methoxy-, (e)
39a7k6nn3w ,
7-methoxy-5-geranoxycoumarin
mfcd00210506
SCHEMBL1714211
SCHEMBL1714204
5-{[(2e)-3,7-dimethylocta-2,6-dien-1-yl]oxy}-7-methoxy-2h-chromen-2-one
AKOS027381401
5-(geranyloxy)-herniarin
Q13461252
(e)-5-((3,7-dimethylocta-2,6-dien-1-yl)oxy)-7-methoxy-2h-chromen-2-one
CHEMBL4176013
XG163780
CS-0144151
HY-N8431
14087-05-9
coumarin, 5-[(3,7-dimethyl-2,6-octadienyl)oxy]-7-methoxy-, (e)-
2h-1-benzopyran-2-one, 5-[[(2e)-3,7-dimethyl-2,6-octadien-1-yl]oxy]-7-methoxy-
5-[(3,7-dimethyl-2,6-octadien-1-yl)oxy]-7-methoxy-2h-1-benzopyran-2-one
5-[[(2e)-3,7-dimethyl-2,6-octadien-1-yl]oxy]-7-methoxy-2h-1-benzopyran-2-one
2h-1-benzopyran-2-one, 5-[(3,7-dimethyl-2,6-octadien-1-yl)oxy]-7-methoxy-
DTXSID001045382
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
terpene lactone
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1359333Induction of melanogenesis in mouse Melan-a cells assessed as effect on tanning property at 40 uM after 48 hrs2018European journal of medicinal chemistry, May-25, Volume: 152Natural oxyprenylated coumarins are modulators of melanogenesis.
AID1359332Cytotoxicity against mouse Melan-a cells assessed as effect on cell viability at <2 uM after 24 to 72 hrs by trypan blue exclusion assay2018European journal of medicinal chemistry, May-25, Volume: 152Natural oxyprenylated coumarins are modulators of melanogenesis.
AID1359334Inhibition of melanogenesis in mouse Melan-a cells assessed as effect on whitening property at 40 uM after 48 hrs2018European journal of medicinal chemistry, May-25, Volume: 152Natural oxyprenylated coumarins are modulators of melanogenesis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.83

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.83 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.83)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]